Drug
clofarabine (IV formulation)
clofarabine (IV formulation) is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Phase Distribution
Ph phase_1
1
20%
Ph phase_2
3
60%
Ph phase_3
1
20%
Phase Distribution
1
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)
NCT00042341
completedphase_2
Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients
NCT00042354
completedphase_3
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
NCT00317642
completedphase_2
Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia
NCT00044889
completedphase_1
Clofarabine in Adult Patients With Advanced Solid Tumors
NCT00125840
Clinical Trials (5)
Showing 5 of 5 trials
NCT00042341Phase 2
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)
NCT00042354Phase 2
Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients
NCT00317642Phase 3
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
NCT00044889Phase 2
Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia
NCT00125840Phase 1
Clofarabine in Adult Patients With Advanced Solid Tumors
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5